DIAN-TU is launching the DIAN-TU-003 Amyloid Removal Trial (ART) to enable continued treatment for the DIAN-TU-001 Gantenerumab Open Label Extension (OLE) participants and address questions regarding the effects of removing amyloid plaques to normal levels on cognitive symptoms, clinical progression and disease processes.
We are now pleased to announce plans to re-launch the DIAN-TU-002 Primary Prevention Trial with remternetug in collaboration with Eli Lilly and Company (Lilly).
Update to the 18 August 2023 announcement by the Knight Family DIAN-TU regarding the DIAN-TU-001 Open Label Extension (OLE) Study
This announcement is regarding the Knight Family DIAN-TU Open Label Extension (OLE) Study with gantenerumab (made by Roche and Genentech)
Questions and concerns from sites and participants regarding the status of the DIAN-TU-001 gantenerumab open label extension (OLE) study and next steps in the study.
Response to Eisai’s 06 January 2023 announcement regarding the FDA’s accelerated approval of lecanemab for the treatment of symptomatic Alzheimer’s disease (AD)
Update to the 15 November 2022 announcement by the Knight Family Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) regarding the DIAN-TU-002 Primary Prevention Trial with Gantenerumab.
The statement below is in response to the 14 November 2022 announcement regarding the results from the GRADUATE I and II AD studies found on Roche’s website. Roche, known as Genentech in the United States, and the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) at Washington University in St. Louis have been evaluating gantenerumab in […]
Response to the 14-November-2022 announcement regarding the results from the GRADUATE I and II AD studies found on Roche’s website
Response to the 28 September 2022 announcement found on Eisai’s website.